TCT 2009 schedule: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Apalmer (talk | contribs)
nocaptcha
14,582 edits
Apalmer (talk | contribs)
nocaptcha
14,582 edits
 
(26 intermediate revisions by 2 users not shown)
Line 1: Line 1:
Here is the page we will use to coordinate the TV events at TCT 2009.
Here is the page we will use to coordinate the TV events at TCT 2009. The filming will take place in Room East 264 at the Moscone Convention Center.


----
----
Line 5: Line 5:


==Click on Date for Detailed Schedule==
==Click on Date for Detailed Schedule==
[[{{PAGENAME}}#Monday September 21, 2009|Monday September 21, 2009]]


[[{{PAGENAME}}#Tuesday September 22, 2009|Tuesday September 22, 2009]]
[[{{PAGENAME}}#Tuesday September 22, 2009|Tuesday September 22, 2009]]
Line 18: Line 16:
----
----


== Monday September 21, 2009==
===1:05 PM===
''1:05 PM - 1:15 PM''
*'''Event:''' The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
*'''Room:''' 104
===1:51 PM===
''1:51 PM - 2:03 PM''
*'''Event:''' The Drug-Eluting Stent Summit Part 1: Appropriate Utilization of Current Generation Devices. Session III. DES Safety Considerations
*'''Room:''' 104
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
== Tuesday September 22, 2009==


===10:00 AM===
==Tuesday September 22, 2009==
''10:00 AM - 12:00 PM''
*'''Event:''' Oral Abstracts- AMI
*'''Room:''' 125


===12:30 PM===
===12:30 PM===
''12:30 PM - 1:00 PM''
''12:30 PM - 1:00 PM''
*'''Event:''' Interview
*'''Interviewee:''' Peter Smits
*'''Room:''' East 264
*'''Trial:''' COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
*'''Interviewee:''' Pieter C. Smits
*'''Embargo lift:''' Wednesday 9/23 12:30 PM
*'''Confirmed:''' Yes
*'''Trial: ''' COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents  
*'''Phone number:'''


===1:00 PM===
===1:00 PM===
''1:00 PM - 1:30 PM''
''1:00 PM - 1:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Shamir Mehta
*'''Interviewee:''' Shamir Mehta
*'''Confirmed:''' Yes
*'''Trial: ''' CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
*'''Trial: ''' CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS  
*'''Embargo lift:''' Thursday 9/24 12:30 PM 
*'''Phone number:'''
 
===2:00 PM===
''2:00 PM - 2:30 PM''
*'''Interviewee:''' John Spertus
*'''Trial: ''' NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
*'''Embargo lift:''' Thursday 9/24 3:00 PM
 
===2:30 PM===
''2:30 PM - 3:00 PM''
*'''Interviewee:''' Eberhard Grube
*'''Trial: ''' BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
*'''Embargo lift:''' Thursday 9/24 3:30 PM
 
===3:00 PM===
''3:00 PM - 3:30 PM''
*'''Interviewee:''' David Allie
*'''Trial: ''' CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
*'''Embargo lift:''' Thursday 9/24 5:10 PM
 
===3:30 PM===
''3:30 PM - 4:00 PM''
*'''Interviewee:''' Douglas Losordo
*'''Trial: ''' ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
*'''Embargo lift:''' Thursday 9/24 5:40 PM
 
===4:00 PM===
''4:00 PM - 4:30 PM''
*'''Interviewee:''' Gary Ansel
*'''Trial: ''' ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
*'''Embargo lift:''' Thursday 9/24 5:25 PM
 
 
 
===5:00 PM===
''5:00 PM - 5:30 PM''
*'''Interviewee:'''  Francesco  Prati
*'''Trial:''' COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT 
*'''Embargo lift:''' Thursday 9/24 4:05 PM




Line 64: Line 76:
===8:30 AM===
===8:30 AM===
''8:30 AM - 9:00 AM''
''8:30 AM - 9:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' William Fearon
*'''Interviewee:''' William Fearon
*'''Confirmed:''' Yes
*'''Trial: ''' FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease  
*'''Trial: ''' FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease  
*'''Phone number:'''


===9:00 AM===
===9:00 AM===
''9:00 AM - 9:30 AM''
''9:00 AM - 9:30 AM''
*'''Event:''' Interview
*'''Interviewee:''' Josef Veselka
*'''Room:''' East 264
*'''Trial: ''' STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina 
*'''Interviewee:''' Lorenz Raber
*'''Confirmed:''' Yes
*'''Trial: ''' SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents                           
*'''Phone number:'''
 
===9:30 AM===
''9:30 AM - 10:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Volker Klauss
*'''Confirmed:''' Yes
*'''Trial: ''' LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
*'''Phone number:'''


===10:00 AM===
===10:00 AM===
''10:00 AM - 10:30 AM''
''10:00 AM - 10:30 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Deepak Bhatt
*'''Interviewee:''' Deepak Bhatt
*'''Confirmed:''' Yes
*'''Trial: ''' 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel  
*'''Trial: ''' 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel  
2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
*'''Phone number:'''
 
===10:15 AM===
''10:15 AM - 10:30 AM''
*'''Interviewee:''' Douglas Losordo
*'''Trial: ''' ACT 34-CMI


===10:30 AM===
===10:30 AM===
''10:30 AM - 11:00 AM''
''10:30 AM - 11:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' David Cohen
*'''Interviewee:''' David Cohen
*'''Confirmed:''' Yes
*'''Trial: ''' TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI   
*'''Trial: ''' TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI   
*'''Phone number:'''


===11:00 AM===
===11:00 AM===
''11:00 AM - 11:30 AM''
''11:00 AM - 11:30 AM''
*'''Event:''' Interview
*'''Interviewee:''' Michelle O'Donoghue
*'''Room:''' East 264
*'''Trial: ''' The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in
*'''Interviewee:''' Chris Cannon
Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial
*'''Confirmed:''' Yes
*'''Trial: ''' PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
*'''Phone number:'''


===12:00 PM===
===12:00 PM===
''12:00 PM - 12:30 PM''
''12:00 PM - 12:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Robert Byrne
*'''Interviewee:''' Robert Byrne
*'''Confirmed:''' Yes
*'''Trial: ''' ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents  
*'''Trial: ''' ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents  
*'''Phone number:'''   


===12:45 PM===
===1:00 PM===
''12:45 PM - 12:50 PM''
''1:00 PM - 1:30 PM''
*'''Event:''' Open Issues I: Adjunct Pharmacology. Schedule
*'''Interviewee:''' Sunil Rao
*'''Room:''' 130
*'''Trial: ''' Radial Artery Procedures (not a trial)


===1:35 PM===
===1:30 PM===
''1:35 PM - 1:45 PM''
''1:30 PM - 2:00 PM''
*'''Event:''' Open Issues I: Adjunct Pharmacology. Schedule
*'''Interviewee:''' Stephan Windecker
*'''Room:''' 130
*'''Trial: ''' SIRTAX-LATE.  5-Year Clinical and Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents


===4:00 PM===
===3:45 PM===
''4:00 PM - 4:45 PM''
''3:45 PM - 4:00 PM''
*'''Event:''' Main Arena I. Plenary Session #7 Personalized Clinical Decision-Making Case Study: The Ischemia vs. Bleeding Controversy
*'''Interviewee:''' Christopher Cannon
*'''Room:''' Esplanade Ballroom
*'''Trial: ''' PLATO INVASIVE.  A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy


''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
Line 145: Line 130:
== Thursday September 24, 2009==
== Thursday September 24, 2009==


===8:46 AM===
===12:45 PM===
''8:46 AM - 11:11 AM''
''12:45 PM - 1:15 PM''
*'''Event:''' Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 2: Current Choices in Antithrombin Therapy for ACS and PCI
*'''Interviewee:''' Cheol Whan Lee
*'''Room:''' 135
*'''Trial: ''' 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel 
 
===1:15 PM===
''1:15 PM - 1:45 PM''
*'''Interviewee:''' Flavio Ribichini 
*'''Trial: ''' CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation   
 
===2:45 PM===
''2:45 PM - 3:15 PM''
*'''Interviewee:''' Junbo Ge
*'''Trial: ''' NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI   
 
===3:15 PM===
''3:15 PM - 3:45 PM''
*'''Interviewee:''' Giulio Guagliumi
*'''Trial: ''' OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT   
 
===3:45 PM===
''3:45 PM - 4:15 PM''
*'''Interviewee:''' Josep Rodes-Cabau
*'''Trial: ''' The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis   
 
===5:15 PM===
''5:15 PM - 5:45 PM''
*'''Interviewee:''' Ran Kornowski
*'''Topic:''' the changing landscape of interventional cardiology


===11:45 PM===
===5:45 PM===
''11:45 AM - 11:57 AM''
''5:45 PM - 6:00 PM''
*'''Event:''' Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
*'''Interviewee:''' Patrick Ohlmann
*'''Room:''' 135
*'''Trial: ''' MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI 


===12:09 PM===
===6:00 PM===
''12:09 PM - 12:24 PM''
''6:00 PM - 6:30 PM''
*'''Event:''' Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Anti-Thrombins, Xa Inhibitors and Emerging Agents. Session 3: Emerging Alternatives for Antiocoagulation for ACS and PCI
*'''Interviewee:''' John Spertus
*'''Room:''' 135
*'''Trial: ''' NEVO RES-ELUTION


===5:02 PM===
''5:02 PM - 5:14 PM''
*'''Event:''' Balancing Safety and Efficacy of Antithrombotic Therapies for PCI and ACS. Antiplatelet Agents, Bleeding, and Ischemia
*'''Room:''' 135


''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''


== Friday September 25, 2009==
== Friday September 25, 2009==
===8:30 AM===
''8:30 AM - 9:00 AM''
*'''Interviewee:''' Dirk Walter
*'''Trial: ''' PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
===9:00 AM===
''9:00 AM - 9:30 AM''
*'''Interviewee:''' Volker Klauss
*'''Trial: ''' LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer


===10:30 AM===
===10:30 AM===
''10:30 AM - 11:00 AM''
''10:30 AM - 11:00 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Simon Redwood
*'''Interviewee:''' Simon Redwood
*'''Confirmed:''' Yes
*'''Trial: ''' BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
*'''Trial: ''' BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
*'''Phone number:'''


===11:00 AM===
===11:00 AM===
''11:00 AM - 11:30 AM''
''11:00 AM - 11:30 AM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Arnold Seto
*'''Interviewee:''' Arnold Seto
*'''Confirmed:''' Yes
*'''Trial: ''' FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
*'''Trial: ''' FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
*'''Phone number:'''


===12:30 PM===
===12:30 PM===
''12:30 PM - 1:00 PM''
''12:30 PM - 1:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Rolf Michels
*'''Interviewee:''' Rolf Michels
*'''Confirmed:''' Yes
*'''Trial: ''' DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
*'''Trial: ''' DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
*'''Phone number:'''


===1:00 PM===
===1:00 PM===
''1:00 PM - 1:30 PM''
''1:00 PM - 1:30 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Gregg Stone
*'''Interviewee:''' Gregg Stone
*'''Confirmed:''' Yes
*'''Trial: ''' 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
*'''Trial: ''' 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI
*'''Phone number:'''
 
===1:30 PM===
===1:30 PM===
''1:30 PM - 2:00 PM''
''1:30 PM - 2:00 PM''
*'''Event:''' Interview
*'''Room:''' East 264
*'''Interviewee:''' Henry Krum
*'''Interviewee:''' Henry Krum
*'''Confirmed:''' Yes
*'''Trial: ''' SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
*'''Trial: ''' Symplicity I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
*'''Phone number:'''
 
===2:24 PM===
''2:24 PM - 2:36 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
GPIIb/IIIa Inhibitors in ACS: EARLY ACS
*'''Room:''' EBM and Guidelines Theater, Hall D
 
===2:36 PM===
''2:36 PM - 3:12 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7
*'''Room:''' EBM and Guidelines Theater, Hall D
 
===3:00 PM===
''3:00 PM - 3:12 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Aspirin and Clopiodgrel in ACS: CURRENT-OASIS 7
*'''Room:''' EBM and Guidelines Theater, Hall D
 
===3:24 PM===
''3:24 PM - 3:36 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Ticagrelor in ACS: PLATO
*'''Room:''' EBM and Guidelines Theater, Hall D


===3:36 PM===
''3:36 PM - 3:48 PM''
*'''Event:''' Top Interventional Trials of the Last Year: Perspectives from the Experts
Ticagrelor in ACS: PLATO
*'''Room:''' EBM and Guidelines Theater, Hall D


''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]''

Latest revision as of 01:23, 25 September 2009

Here is the page we will use to coordinate the TV events at TCT 2009. The filming will take place in Room East 264 at the Moscone Convention Center.


Click on Date for Detailed Schedule

Tuesday September 22, 2009

Wednesday September 23, 2009

Thursday September 24, 2009

Friday September 25, 2009


Tuesday September 22, 2009

12:30 PM

12:30 PM - 1:00 PM

  • Interviewee: Peter Smits
  • Trial: COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
  • Embargo lift: Wednesday 9/23 12:30 PM

1:00 PM

1:00 PM - 1:30 PM

  • Interviewee: Shamir Mehta
  • Trial: CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
  • Embargo lift: Thursday 9/24 12:30 PM

2:00 PM

2:00 PM - 2:30 PM

  • Interviewee: John Spertus
  • Trial: NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
  • Embargo lift: Thursday 9/24 3:00 PM

2:30 PM

2:30 PM - 3:00 PM

  • Interviewee: Eberhard Grube
  • Trial: BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
  • Embargo lift: Thursday 9/24 3:30 PM

3:00 PM

3:00 PM - 3:30 PM

  • Interviewee: David Allie
  • Trial: CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
  • Embargo lift: Thursday 9/24 5:10 PM

3:30 PM

3:30 PM - 4:00 PM

  • Interviewee: Douglas Losordo
  • Trial: ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
  • Embargo lift: Thursday 9/24 5:40 PM

4:00 PM

4:00 PM - 4:30 PM

  • Interviewee: Gary Ansel
  • Trial: ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
  • Embargo lift: Thursday 9/24 5:25 PM


5:00 PM

5:00 PM - 5:30 PM

  • Interviewee: Francesco Prati
  • Trial: COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT
  • Embargo lift: Thursday 9/24 4:05 PM


Return to top

Wednesday September 23, 2009

8:30 AM

8:30 AM - 9:00 AM

  • Interviewee: William Fearon
  • Trial: FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease

9:00 AM

9:00 AM - 9:30 AM

  • Interviewee: Josef Veselka
  • Trial: STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina

10:00 AM

10:00 AM - 10:30 AM

  • Interviewee: Deepak Bhatt
  • Trial: 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention

10:15 AM

10:15 AM - 10:30 AM

  • Interviewee: Douglas Losordo
  • Trial: ACT 34-CMI

10:30 AM

10:30 AM - 11:00 AM

  • Interviewee: David Cohen
  • Trial: TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI

11:00 AM

11:00 AM - 11:30 AM

  • Interviewee: Michelle O'Donoghue
  • Trial: The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in

Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial

12:00 PM

12:00 PM - 12:30 PM

  • Interviewee: Robert Byrne
  • Trial: ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents

1:00 PM

1:00 PM - 1:30 PM

  • Interviewee: Sunil Rao
  • Trial: Radial Artery Procedures (not a trial)

1:30 PM

1:30 PM - 2:00 PM

  • Interviewee: Stephan Windecker
  • Trial: SIRTAX-LATE. 5-Year Clinical and Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents

3:45 PM

3:45 PM - 4:00 PM

  • Interviewee: Christopher Cannon
  • Trial: PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy

Return to top

Thursday September 24, 2009

12:45 PM

12:45 PM - 1:15 PM

  • Interviewee: Cheol Whan Lee
  • Trial: 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel

1:15 PM

1:15 PM - 1:45 PM

  • Interviewee: Flavio Ribichini
  • Trial: CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation

2:45 PM

2:45 PM - 3:15 PM

  • Interviewee: Junbo Ge
  • Trial: NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI

3:15 PM

3:15 PM - 3:45 PM

  • Interviewee: Giulio Guagliumi
  • Trial: OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT

3:45 PM

3:45 PM - 4:15 PM

  • Interviewee: Josep Rodes-Cabau
  • Trial: The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis

5:15 PM

5:15 PM - 5:45 PM

  • Interviewee: Ran Kornowski
  • Topic: the changing landscape of interventional cardiology

5:45 PM

5:45 PM - 6:00 PM

  • Interviewee: Patrick Ohlmann
  • Trial: MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI

6:00 PM

6:00 PM - 6:30 PM

  • Interviewee: John Spertus
  • Trial: NEVO RES-ELUTION


Return to top

Friday September 25, 2009

8:30 AM

8:30 AM - 9:00 AM

  • Interviewee: Dirk Walter
  • Trial: PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease

9:00 AM

9:00 AM - 9:30 AM

  • Interviewee: Volker Klauss
  • Trial: LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer

10:30 AM

10:30 AM - 11:00 AM

  • Interviewee: Simon Redwood
  • Trial: BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI

11:00 AM

11:00 AM - 11:30 AM

  • Interviewee: Arnold Seto
  • Trial: FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access

12:30 PM

12:30 PM - 1:00 PM

  • Interviewee: Rolf Michels
  • Trial: DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI

1:00 PM

1:00 PM - 1:30 PM

  • Interviewee: Gregg Stone
  • Trial: 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI

1:30 PM

1:30 PM - 2:00 PM

  • Interviewee: Henry Krum
  • Trial: SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension


Return to top

Retrieved from "https://www.wikidoc.org/index.php?title=TCT_2009_schedule&oldid=560911"